Form D · Biotechnology
Metabolics Pharma, Inc.
Philadelphia, PA · CIK 0002037862
Offering snapshot reported Sep 19, 2024 · SEC filing
- Reported sold
- $5.53M Offering amount: $6.3M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 5, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 19, 2024 | Initial | $5,526,626 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-524521
Source: Form D, filed Sep 19, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jay A Brammer | Director |
| John Dessouki | Director, Executive |
| Mark Finn | Director |
| Mark Kamp | Director |
| Richard Larson | Director, Executive |
| Barry Miller | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2005 Market Street Suite 3125
Philadelphia, PA, 19103
Philadelphia, PA, 19103